<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20241001082035
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20241001082035" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 01 Oct 2024 12:20:36 +0000</lastbuilddate>
<pubDate>Tue, 01 Oct 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Relationship Between Renin, Aldosterone, Aldosterone-to-Renin Ratio and Arterial Stiffness and Left Ventricular Mass Index in Young Adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39351674/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001082035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Aldosterone concentration and aldosterone-to-renin ratio were positively associated with the LVMI in young males and females, respectively, independently of systolic blood pressure. Long-term follow-up is required to determine whether the relationship persists over time, and clinical trials are needed to assess the cardiovascular benefits of early interventions to block aldosterone.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 1. doi: 10.1161/CIRCULATIONAHA.124.070039. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Primary aldosteronism, characterized by renin-independent aldosterone production, is associated with adverse cardiovascular remodeling and outcomes. Elevated cardiovascular risk is observed even in subclinical forms of primary aldosteronism according to studies conducted primarily in middle-aged and elderly populations. This study aimed to assess whether early changes in primary aldosteronism biomarkers during young adulthood are associated with arterial stiffness and left ventricular mass index (LVMI) before the onset of overt disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The Raine Study is a longitudinal, population-based cohort study in Western Australia that enrolled women during pregnancy. We analyzed the data from the offspring of these women at 17 (2006-2009) and 27 (2016-2018) years of age. Participants with elevated high-sensitivity C-reactive protein (>;10 mg/L) and female participants who were on oral contraception were excluded. Pulse wave velocity and aortic augmentation index were measured by SphygmoCor Pulse Wave System at both ages, and aortic distensibility and LVMI were measured by cardiac magnetic resonance imaging at 27 years. Multivariable linear regression was used to examine the relationship between plasma renin, aldosterone, or aldosterone-to-renin ratio and arterial stiffness and LVMI. Mediation analysis was used to test the role of systolic blood pressure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This study included 859 participants at 17 (38.0% female) and 758 participants at 27 (33.2% female) years of age. Females had lower renin concentration at both 17 (20.7 mU/L versus 25.7 mU/L; <i>P</i>&lt;0.001) and 27 (12.0 mU/L versus 15.4 mU/L; <i>P</i>&lt;0.001) years of age; hence, the aldosterone-to-renin ratio was significantly higher at both 17 (18.2 versus 13.5; <i>P</i>&lt;0.001) and 27 (21.0 versus 15.6; <i>P</i>&lt;0.001) years of age in females compared with males. At 27 years of age, a significant association was detected between aldosterone and LVMI in males (β=0.009 [95% CI, 0.001-0.017]; <i>P</i>=0.027) and between aldosterone-to-renin ratio and LVMI in females (β=0.098 [95% CI, 0.001-0.196]; <i>P</i>=0.050) independently of systolic blood pressure and other confounders. No association was found between primary aldosteronism biomarkers and measures of arterial stiffness (pulse wave velocity, aortic augmentation index, and aortic distensibility) at either age.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Aldosterone concentration and aldosterone-to-renin ratio were positively associated with the LVMI in young males and females, respectively, independently of systolic blood pressure. Long-term follow-up is required to determine whether the relationship persists over time, and clinical trials are needed to assess the cardiovascular benefits of early interventions to block aldosterone.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39351674/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001082035&v=2.18.0.post9+e462414">39351674</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070039>10.1161/CIRCULATIONAHA.124.070039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39351674</guid>
<pubDate>Tue, 01 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Roshan A Ananda</dc:creator>
<dc:creator>StellaMay Gwini</dc:creator>
<dc:creator>Lawrence J Beilin</dc:creator>
<dc:creator>Markus P Schlaich</dc:creator>
<dc:creator>Michael Stowasser</dc:creator>
<dc:creator>Morag J Young</dc:creator>
<dc:creator>Brendan Adler</dc:creator>
<dc:creator>Peter J Fuller</dc:creator>
<dc:creator>Trevor A Mori</dc:creator>
<dc:creator>Jun Yang</dc:creator>
<dc:date>2024-10-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Relationship Between Renin, Aldosterone, Aldosterone-to-Renin Ratio and Arterial Stiffness and Left Ventricular Mass Index in Young Adults</dc:title>
<dc:identifier>pmid:39351674</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070039</dc:identifier>
</item>
<item>
<title>Pneumonia Induced Rise in Glucagon Promotes Endothelial Damage and Thrombogenicity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39351669/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001082035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 1. doi: 10.1161/CIRCRESAHA.124.324938. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39351669/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001082035&v=2.18.0.post9+e462414">39351669</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324938>10.1161/CIRCRESAHA.124.324938</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39351669</guid>
<pubDate>Tue, 01 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Pegah Ramezani Rad</dc:creator>
<dc:creator>Vanasa Nageswaran</dc:creator>
<dc:creator>Lisa Peters</dc:creator>
<dc:creator>Leander Reinshagen</dc:creator>
<dc:creator>Johann Roessler</dc:creator>
<dc:creator>Szandor Simmons</dc:creator>
<dc:creator>Erik Asmus</dc:creator>
<dc:creator>Corey Wittig</dc:creator>
<dc:creator>Markus C Brack</dc:creator>
<dc:creator>Geraldine Nouailles</dc:creator>
<dc:creator>Emiel P C van der Vorst</dc:creator>
<dc:creator>Sanne L Maas</dc:creator>
<dc:creator>Kristina Sonnenschein</dc:creator>
<dc:creator>Barbara Verhaar</dc:creator>
<dc:creator>Robert Szulcek</dc:creator>
<dc:creator>Martin Witzenrath</dc:creator>
<dc:creator>Ulf Landmesser</dc:creator>
<dc:creator>Wolfgang M Kuebler</dc:creator>
<dc:creator>Arash Haghikia</dc:creator>
<dc:date>2024-10-01</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Pneumonia Induced Rise in Glucagon Promotes Endothelial Damage and Thrombogenicity</dc:title>
<dc:identifier>pmid:39351669</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324938</dc:identifier>
</item>
<item>
<title>Transformation of the Kidney into a Pathological Neuro-Immune-Endocrine Organ</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39351666/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001082035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 1. doi: 10.1161/CIRCRESAHA.124.325305. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39351666/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001082035&v=2.18.0.post9+e462414">39351666</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325305>10.1161/CIRCRESAHA.124.325305</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39351666</guid>
<pubDate>Tue, 01 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Manako Yamaguchi</dc:creator>
<dc:creator>Lucas Ferreira de Almeida</dc:creator>
<dc:creator>Hiroki Yamaguchi</dc:creator>
<dc:creator>Xiuyin Liang</dc:creator>
<dc:creator>Jason P Smith</dc:creator>
<dc:creator>Silvia Medrano</dc:creator>
<dc:creator>Maria Luisa S Sequeira Lopez</dc:creator>
<dc:creator>R Ariel Gomez</dc:creator>
<dc:date>2024-10-01</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Transformation of the Kidney into a Pathological Neuro-Immune-Endocrine Organ</dc:title>
<dc:identifier>pmid:39351666</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325305</dc:identifier>
</item>
<item>
<title>Unveiling the Hidden Layers of Hypertensive Heart Disease Through Quantitative PET Imaging</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39348457/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001082035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct;150(14):1087-1089. doi: 10.1161/CIRCULATIONAHA.124.071479. Epub 2024 Sep 30.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39348457/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001082035&v=2.18.0.post9+e462414">39348457</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071479>10.1161/CIRCULATIONAHA.124.071479</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39348457</guid>
<pubDate>Mon, 30 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Andreas A Giannopoulos</dc:creator>
<dc:creator>Alessia Gimelli</dc:creator>
<dc:date>2024-09-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Unveiling the Hidden Layers of Hypertensive Heart Disease Through Quantitative PET Imaging</dc:title>
<dc:identifier>pmid:39348457</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071479</dc:identifier>
</item>
<item>
<title>Prescribing a New Treatment in Heart Disease Communication</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39348456/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001082035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct;150(14):1070-1071. doi: 10.1161/CIRCULATIONAHA.124.069581. Epub 2024 Sep 30.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39348456/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001082035&v=2.18.0.post9+e462414">39348456</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069581>10.1161/CIRCULATIONAHA.124.069581</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39348456</guid>
<pubDate>Mon, 30 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Wyatt G Paltzer</dc:creator>
<dc:creator>Dietram A Scheufele</dc:creator>
<dc:date>2024-09-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Prescribing a New Treatment in Heart Disease Communication</dc:title>
<dc:identifier>pmid:39348456</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069581</dc:identifier>
</item>
<item>
<title>Improved Access to Genetics Care is Needed to Address Health Inequities in ATTRv Amyloidosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39348455/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001082035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct;150(14):1072-1074. doi: 10.1161/CIRCULATIONAHA.124.070525. Epub 2024 Sep 30.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39348455/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001082035&v=2.18.0.post9+e462414">39348455</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070525>10.1161/CIRCULATIONAHA.124.070525</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39348455</guid>
<pubDate>Mon, 30 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Lathan Liou</dc:creator>
<dc:creator>Mathew S Maurer</dc:creator>
<dc:creator>Amy R Kontorovich</dc:creator>
<dc:date>2024-09-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Improved Access to Genetics Care is Needed to Address Health Inequities in ATTRv Amyloidosis</dc:title>
<dc:identifier>pmid:39348455</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070525</dc:identifier>
</item>
<item>
<title>Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Elevation Myocardial Infarction: STREAM-2 1-Year Mortality Follow-Up</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39348454/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001082035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct;150(14):1151-1153. doi: 10.1161/CIRCULATIONAHA.124.070347. Epub 2024 Sep 30.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39348454/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001082035&v=2.18.0.post9+e462414">39348454</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070347>10.1161/CIRCULATIONAHA.124.070347</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39348454</guid>
<pubDate>Mon, 30 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Peter R Sinnaeve</dc:creator>
<dc:creator>Robert C Welsh</dc:creator>
<dc:creator>Alexandra Arias Mendoza</dc:creator>
<dc:creator>Arsen D Ristić</dc:creator>
<dc:creator>Oleg V Averkov</dc:creator>
<dc:creator>Yves Lambert</dc:creator>
<dc:creator>José F Kerr Saraiva</dc:creator>
<dc:creator>Pablo Sepulveda</dc:creator>
<dc:creator>Fernando Rosell-Ortiz</dc:creator>
<dc:creator>John K French</dc:creator>
<dc:creator>Ljilja B Musić</dc:creator>
<dc:creator>Katleen Vandenberghe</dc:creator>
<dc:creator>Kris Bogaerts</dc:creator>
<dc:creator>Thierry Danays</dc:creator>
<dc:creator>Kevin R Bainey</dc:creator>
<dc:creator>Paul W Armstrong</dc:creator>
<dc:creator>Frans Van de Werf</dc:creator>
<dc:creator>STREAM-2 Investigators</dc:creator>
<dc:date>2024-09-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Elevation Myocardial Infarction: STREAM-2 1-Year Mortality Follow-Up</dc:title>
<dc:identifier>pmid:39348454</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070347</dc:identifier>
</item>
<item>
<title>Coronary Artery Bypass Grafting: Past and Future</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39348453/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001082035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct;150(14):1067-1069. doi: 10.1161/CIRCULATIONAHA.124.068312. Epub 2024 Sep 30.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39348453/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001082035&v=2.18.0.post9+e462414">39348453</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068312>10.1161/CIRCULATIONAHA.124.068312</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39348453</guid>
<pubDate>Mon, 30 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Marc Ruel</dc:creator>
<dc:creator>Joanna Chikwe</dc:creator>
<dc:date>2024-09-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Coronary Artery Bypass Grafting: Past and Future</dc:title>
<dc:identifier>pmid:39348453</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068312</dc:identifier>
</item>
<item>
<title>Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction: Primary Results of the EMBARK-HFpEF Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39347697/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001082035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In an open-label trial in patients with HFpEF with LVEF of 60% or greater, mavacamten was associated with improvements in biomarkers of cardiac wall stress and injury, with no sustained reductions in LVEF observed.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 30. doi: 10.1001/jamacardio.2024.3810. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Patients with heart failure with preserved ejection fraction (HFpEF) who have left ventricular ejection fraction (LVEF) of 60% or greater have limited treatment options.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To examine the effects of cardiac myosin inhibition with mavacamten in patients with HFpEF with LVEF of 60% or greater.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The EMBARK-HFpEF trial was a phase 2a, open-label, single-arm, multicenter trial conducted from November 6, 2020, to February 26, 2024, at 20 sites in the US and Canada. Patients with symptomatic HFpEF (defined as a New York Heart Association [NYHA] functional class II or III), LVEF of 60% or greater, elevated N-terminal pro-B-type natriuretic peptide (NTproBNP), and left ventricular hypertrophy were eligible for inclusion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Mavacamten treatment for 26 weeks, starting at 2.5 mg and potentially titrated up to 5 mg at week 14 based on prespecified LVEF and NTproBNP criteria.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Primary efficacy end points (measured as the change from baseline to week 26) included NTproBNP and high-sensitivity troponin T (hsTnT); additional efficacy end points included changes in high-sensitivity troponin I (hsTnI), NYHA functional class, and echocardiographic parameters (resting and peak exercise). Safety end points included treatment-emergent adverse events and reductions in LVEF to less than 30%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 30 patients were enrolled and treated with mavacamten. Median (IQR) patient age was 76 (70-80) years, and 16 patients (53.3%) were female. From baseline to week 26, mavacamten was associated with reductions in NTproBNP (mean reduction, -26%; 95% CI, -44% to -4%; P = .04), hsTnT (mean reduction, -13%; 95% CI, -23% to -3%; P = .02), and hsTnI (mean reduction, -20%; 95% CI, -32% to -6%; P = .01). Cardiac biomarker values returned toward baseline levels 8 weeks after drug discontinuation. NYHA class improved in 10 of 24 patients (41.7%) who had evaluable NYHA class data at the end of treatment, and improvements in echocardiographic markers of LV diastolic function were observed. Mean LVEF decreased by 3.2 absolute percentage points (95% CI, 1.1-5.4; P = .005) during treatment. Mavacamten was interrupted in 3 patients (10% of the study population; 95% CI, 2.1%-26.5%) due to protocol prespecified criteria of LVEF less than 50% (n = 2) or a more than 20% relative decrease from baseline (n = 1; nadir LVEF, 58%), with LVEF recovery observed in all 3 patients. There were no deaths or instances of LVEF less than 30%; 1 patient had worsening heart failure deemed unrelated to the study drug.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In an open-label trial in patients with HFpEF with LVEF of 60% or greater, mavacamten was associated with improvements in biomarkers of cardiac wall stress and injury, with no sustained reductions in LVEF observed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04766892.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39347697/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001082035&v=2.18.0.post9+e462414">39347697</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3810>10.1001/jamacardio.2024.3810</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39347697</guid>
<pubDate>Mon, 30 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Marzia Rigolli</dc:creator>
<dc:creator>Atefeh Javidialsaadi</dc:creator>
<dc:creator>Ravi B Patel</dc:creator>
<dc:creator>Suhail Khadra</dc:creator>
<dc:creator>Parag Goyal</dc:creator>
<dc:creator>Sean Little</dc:creator>
<dc:creator>Omar Wever-Pinzon</dc:creator>
<dc:creator>Anjali Tiku Owens</dc:creator>
<dc:creator>Hicham Skali</dc:creator>
<dc:creator>Pankaj Arora</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-09-30</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction: Primary Results of the EMBARK-HFpEF Trial</dc:title>
<dc:identifier>pmid:39347697</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3810</dc:identifier>
</item>
<item>
<title>Mucolipidosis III: a rare phenocopy of inherited metabolic cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39344930/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001082035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 30:ehae636. doi: 10.1093/eurheartj/ehae636. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39344930/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001082035&v=2.18.0.post9+e462414">39344930</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae636>10.1093/eurheartj/ehae636</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39344930</guid>
<pubDate>Mon, 30 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Xia Gu</dc:creator>
<dc:creator>Linlin Dai</dc:creator>
<dc:creator>Minjie Lu</dc:creator>
<dc:date>2024-09-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mucolipidosis III: a rare phenocopy of inherited metabolic cardiomyopathy</dc:title>
<dc:identifier>pmid:39344930</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae636</dc:identifier>
</item>
<item>
<title>Fusion mixed reality: a novel approach to merge the physical and virtual cath lab</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39344929/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001082035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 30:ehae632. doi: 10.1093/eurheartj/ehae632. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39344929/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001082035&v=2.18.0.post9+e462414">39344929</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae632>10.1093/eurheartj/ehae632</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39344929</guid>
<pubDate>Mon, 30 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>João Silva Marques</dc:creator>
<dc:creator>Catarina Oliveira</dc:creator>
<dc:creator>Fausto J Pinto</dc:creator>
<dc:date>2024-09-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Fusion mixed reality: a novel approach to merge the physical and virtual cath lab</dc:title>
<dc:identifier>pmid:39344929</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae632</dc:identifier>
</item>
<item>
<title>Cardiovascular events following coronavirus disease 2019 vaccination in adults: a nationwide Swedish study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39344920/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001082035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Risk of myopericarditis (mRNA vaccines only), extrasystoles, and transient ischaemic attack was transiently increased after COVID-19 vaccination, but full vaccination substantially reduced the risk of several more severe COVID-19-associated cardiovascular outcomes, underscoring the protective benefits of complete vaccination.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 30:ehae639. doi: 10.1093/eurheartj/ehae639. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: While the rationale for coronavirus disease 2019 (COVID-19) vaccination is to reduce complications and overall mortality, some cardiovascular complications from the vaccine itself have been demonstrated. Myocarditis and pericarditis are recognized as rare acute adverse events after mRNA vaccines in young males, while evidence regarding other cardiovascular events remains limited and inconsistent. This study assessed the risks of several cardiovascular and cerebrovascular events in a Swedish nationwide register-based cohort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Post-vaccination risk of myocarditis/pericarditis, dysrhythmias, heart failure, myocardial infarction, and cerebrovascular events (transient ischaemic attack and stroke) in several risk windows after each vaccine dose were assessed among all Swedish adults (n = 8 070 674). Hazard ratios (HRs) with 95% confidence intervals (95% CIs) compared with unvaccinated were estimated from Cox regression models adjusted for potential confounders.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: For most studied outcomes, decreased risks of cardiovascular events post-vaccination were observed, especially after dose three (HRs for dose three ranging from .69 to .81), while replicating the increased risk of myocarditis and pericarditis 1-2 weeks after COVID-19 mRNA vaccination. Slightly increased risks, similar across vaccines, were observed for extrasystoles [HR 1.17 (95% CI 1.06-1.28) for dose one and HR 1.22 (95% CI 1.10-1.36) for dose two, stronger in elderly and males] but not for arrhythmias and for transient ischaemic attack [HR 1.13 (95% CI 1.05-1.23), mainly in elderly] but not for stroke.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Risk of myopericarditis (mRNA vaccines only), extrasystoles, and transient ischaemic attack was transiently increased after COVID-19 vaccination, but full vaccination substantially reduced the risk of several more severe COVID-19-associated cardiovascular outcomes, underscoring the protective benefits of complete vaccination.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39344920/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001082035&v=2.18.0.post9+e462414">39344920</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae639>10.1093/eurheartj/ehae639</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39344920</guid>
<pubDate>Mon, 30 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Yiyi Xu</dc:creator>
<dc:creator>Huiqi Li</dc:creator>
<dc:creator>Ailiana Santosa</dc:creator>
<dc:creator>Björn Wettermark</dc:creator>
<dc:creator>Tove Fall</dc:creator>
<dc:creator>Jonas Björk</dc:creator>
<dc:creator>Mats Börjesson</dc:creator>
<dc:creator>Magnus Gisslén</dc:creator>
<dc:creator>Fredrik Nyberg</dc:creator>
<dc:date>2024-09-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiovascular events following coronavirus disease 2019 vaccination in adults: a nationwide Swedish study</dc:title>
<dc:identifier>pmid:39344920</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae639</dc:identifier>
</item>
<item>
<title>Clinical Use of Bedside Portable Ultra-Low-Field Brain Magnetic Resonance Imaging in Patients on Extracorporeal Membrane Oxygenation: Results From the Multicenter SAFE MRI ECMO Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39342513/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001082035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study demonstrates that ULF-pMRI can be performed in patients on ECMO across different ECMO cannulation strategies in specially trained intensive care units. The incidence of ABI was high, seen in 44% of ULF-pMRI studies. ULF-pMRI imaging appears to be more sensitive to ABI, particularly ischemic stroke, compared with head computed tomography.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 29. doi: 10.1161/CIRCULATIONAHA.124.069187. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Early detection of acute brain injury (ABI) at the bedside is critical in improving survival for patients with extracorporeal membrane oxygenation (ECMO) support. We aimed to examine the safety of ultra-low-field (ULF; 0.064-T) portable magnetic resonance imaging (pMRI) in patients undergoing ECMO and to investigate the ABI frequency and types with ULF-pMRI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a multicenter prospective observational study (SAFE MRI ECMO study [Assessing the Safety and Feasibility of Bedside Portable Low-Field Brain Magnetic Resonance Imaging in Patients on ECMO]; NCT05469139) from 2 tertiary centers (Johns Hopkins, Baltimore, MD and University of Texas-Houston) with specially trained intensive care units. Primary outcomes were safety of ULF-pMRI during ECMO support, defined as completion of ULF-pMRI without significant adverse events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 53 eligible patients, 3 were not scanned because of a large head size that did not fit within the head coil. ULF-pMRI was performed in 50 patients (median age, 58 years; 52% male), with 34 patients (68%) on venoarterial ECMO and 16 patients (32%) on venovenous ECMO. Of 34 patients on venoarterial ECMO, 11 (22%) were centrally cannulated and 23 (46%) were peripherally cannulated. In venovenous ECMO, 9 (18%) had single-lumen cannulation and 7 (14%) had double-lumen cannulation. Of 50 patients, adverse events occurred in 3 patients (6%), with 2 minor adverse events (ECMO suction event; transient low ECMO flow) and one serious adverse event (intra-aortic balloon pump malfunction attributable to electrocardiographic artifacts). All images demonstrated discernible intracranial pathologies with good quality. ABI was observed in 22 patients (44%). Ischemic stroke (36%) was the most common type of ABI, followed by intracranial hemorrhage (6%) and hypoxic-ischemic brain injury (4%). Of 18 patients (36%) with both ULF-pMRI and head computed tomography within 24 hours, ABI was observed in 9 patients with a total of 10 events (8 ischemic, 2 hemorrhagic events). Of the 8 ischemic events, pMRI observed all 8, and head computed tomography observed only 4 events. For intracranial hemorrhage, pMRI observed only 1 of them, and head computed tomography observed both (2 events).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study demonstrates that ULF-pMRI can be performed in patients on ECMO across different ECMO cannulation strategies in specially trained intensive care units. The incidence of ABI was high, seen in 44% of ULF-pMRI studies. ULF-pMRI imaging appears to be more sensitive to ABI, particularly ischemic stroke, compared with head computed tomography.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39342513/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001082035&v=2.18.0.post9+e462414">39342513</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069187>10.1161/CIRCULATIONAHA.124.069187</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39342513</guid>
<pubDate>Sun, 29 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Sung-Min Cho</dc:creator>
<dc:creator>Shivalika Khanduja</dc:creator>
<dc:creator>Christopher Wilcox</dc:creator>
<dc:creator>Kha Dinh</dc:creator>
<dc:creator>Jiah Kim</dc:creator>
<dc:creator>Jin Kook Kang</dc:creator>
<dc:creator>Ifeanyi David Chinedozi</dc:creator>
<dc:creator>Zachary Darby</dc:creator>
<dc:creator>Matthew Acton</dc:creator>
<dc:creator>Hannah Rando</dc:creator>
<dc:creator>Jessica Briscoe</dc:creator>
<dc:creator>Errol L Bush</dc:creator>
<dc:creator>Haris I Sair</dc:creator>
<dc:creator>John Pitts</dc:creator>
<dc:creator>Lori R Arlinghaus</dc:creator>
<dc:creator>Audrey-Carelle N Wandji</dc:creator>
<dc:creator>Elena Moreno</dc:creator>
<dc:creator>Glenda Torres</dc:creator>
<dc:creator>Bindu Akkanti</dc:creator>
<dc:creator>Jose Gavito-Higuera</dc:creator>
<dc:creator>Steven Keller</dc:creator>
<dc:creator>HuiMahn A Choi</dc:creator>
<dc:creator>Bo Soo Kim</dc:creator>
<dc:creator>Aaron Gusdon</dc:creator>
<dc:creator>Glenn J Whitman</dc:creator>
<dc:creator>SAFE MRI ECMO Investigators</dc:creator>
<dc:date>2024-09-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Clinical Use of Bedside Portable Ultra-Low-Field Brain Magnetic Resonance Imaging in Patients on Extracorporeal Membrane Oxygenation: Results From the Multicenter SAFE MRI ECMO Study</dc:title>
<dc:identifier>pmid:39342513</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069187</dc:identifier>
</item>
<item>
<title>Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: a Prespecified Analysis of The FINEARTS-HF Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39342512/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001082035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with HFmrEF/HFpEF, finerenone reduced the risk of cardiovascular death and worsening heart failure events, irrespective of LVEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 29. doi: 10.1161/CIRCULATIONAHA.124.072011. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The effect of treatments for heart failure may vary among patients according to left ventricular ejection fraction (LVEF). In the FINEARTS-HF, the nonsteroidal MRA finerenone reduced the risk of cardiovascular death and total worsening heart failure events in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). We examined the effect of finerenone according to LVEF in FINEARTS-HF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: FINEARTS-HF was a randomized, placebo-controlled trial examining the efficacy and safety of finerenone in patients with heart failure and LVEF &amp;#x226540%. The treatment effect of finerenone was examined in prespecified analyses according to LVEF categories (&lt;50%, ≥50 to &lt;60%, and ≥60%) and with LVEF as a continuous variable. The primary outcome was a composite of total (first and recurrent) worsening HF events and cardiovascular death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Baseline LVEF data were available for 5993 of the 6001 participants in FINEARTS-HF. Mean and median LVEF were 53 ± 8% and 53% (IQR 46% -58%), respectively. LVEF was &lt;50% in 2172 (36), between 50 to &lt;60% in 2674 (45%), and ≥60% in 1147 (19%). Patients with a higher LVEF were older, more commonly female, were less likely to have a history of coronary artery disease, and more frequently had a history of hypertension and chronic kidney disease compared to those with a lower LVEF. Finerenone reduced the risk of cardiovascular death and total heart failure events consistently across LVEF categories: LVEF &lt;50% rate ratio (RR) = 0.84 (95% CI 0.68, 1.03), LVEF ≥50 to &lt;60% RR = 0.80 (0.66, 0.97) and LVEF ≥60% RR = 0.94 (0.70, 1.25); p interaction = 0.70. There was no modification of the benefit of finerenone across the range of LVEF when analyzed as a continuous variable (p interaction = 0.28). There was a similar consistent effect of finerenone on reducing the total number of worsening heart failure events (continuous p interaction = 0.26).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with HFmrEF/HFpEF, finerenone reduced the risk of cardiovascular death and worsening heart failure events, irrespective of LVEF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39342512/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001082035&v=2.18.0.post9+e462414">39342512</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072011>10.1161/CIRCULATIONAHA.124.072011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39342512</guid>
<pubDate>Sun, 29 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Kieran F Docherty</dc:creator>
<dc:creator>Alasdair D Henderson</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Katharina Mueller</dc:creator>
<dc:creator>Prabhakar Viswanathan</dc:creator>
<dc:creator>Andrea Scalise</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>John Jv McMurray</dc:creator>
<dc:date>2024-09-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: a Prespecified Analysis of The FINEARTS-HF Trial</dc:title>
<dc:identifier>pmid:39342512</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072011</dc:identifier>
</item>
<item>
<title>New Guidelines and a focus on ischaemic heart disease, atrial fibrillation, innovative treatments of channelopathies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39342493/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001082035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 29;45(36):3299-3302. doi: 10.1093/eurheartj/ehae638.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39342493/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001082035&v=2.18.0.post9+e462414">39342493</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae638>10.1093/eurheartj/ehae638</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39342493</guid>
<pubDate>Sun, 29 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-09-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>New Guidelines and a focus on ischaemic heart disease, atrial fibrillation, innovative treatments of channelopathies</dc:title>
<dc:identifier>pmid:39342493</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae638</dc:identifier>
</item>
<item>
<title>Effects of the Non-Steroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39340828/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001082035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The treatment benefits of the non-steroidal MRA finerenone were observed irrespective of concomitant use of an SGLT2i. These data suggest that the combined use of SGLT2i and a non-steroidal MRA may provide additive protection against cardiovascular events in patients with HF with mildly reduced or preserved ejection fraction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 28. doi: 10.1161/CIRCULATIONAHA.124.072055. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Patients with heart failure (HF) with mildly reduced or preserved ejection fraction face heightened long-term risks of morbidity and mortality. The sodium glucose-co-transporter-2 inhibitors (SGLT2i) and the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone have both been shown to reduce the risk of cardiovascular events in this population, but the effects of their combined use are not known.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: FINEARTS-HF was a randomized, double-blind, placebo-controlled trial of finerenone in patients with HF and left ventricular ejection fraction (LVEF) ≥40%. Baseline SGLT2i use was a prespecified subgroup. The primary outcome was a composite of total (first and recurrent) worsening HF events and cardiovascular death. We first assessed for evidence of treatment heterogeneity based on baseline SGLT2i use. We further examined SGLT2i uptake during the trial and evaluated the treatment effects of finerenone accounting for baseline and during trial use of SGLT2i in time-varying analyses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 6,001 participants, 817 (13.6%) were treated with an SGLT2i at baseline. During 2.6-years median follow-up, treatment with finerenone similarly reduced the risk of the primary outcome in participants treated with an SGLT2i (rate ratio 0.83; 95% confidence interval 0.60 to 1.16) and without an SGLT2i at baseline (rate ratio 0.85; 95% confidence interval 0.74 to 0.98); P<sub>interaction</sub>=0.76. In follow-up, 980 participants initiated SGLT2i, which was less frequent in the finerenone arm compared with placebo (17.7% vs. 20.1%; hazard ratio 0.86; confidence interval 0.76 to 0.97). Time-updated analyses accounting for baseline and subsequent use of SGLT2i did not meaningfully alter the treatment effects of finerenone on the primary endpoint.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The treatment benefits of the non-steroidal MRA finerenone were observed irrespective of concomitant use of an SGLT2i. These data suggest that the combined use of SGLT2i and a non-steroidal MRA may provide additive protection against cardiovascular events in patients with HF with mildly reduced or preserved ejection fraction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39340828/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001082035&v=2.18.0.post9+e462414">39340828</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072055>10.1161/CIRCULATIONAHA.124.072055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39340828</guid>
<pubDate>Sat, 28 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Ian J Kulac</dc:creator>
<dc:creator>Zi Michael Miao</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Alasdair D Henderson</dc:creator>
<dc:creator>Meike Brinker</dc:creator>
<dc:creator>James Lay-Flurrie</dc:creator>
<dc:creator>Prabhakar Viswanathan</dc:creator>
<dc:creator>Markus Florian Scheerer</dc:creator>
<dc:creator>Andrea Lage</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-09-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effects of the Non-Steroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart Failure</dc:title>
<dc:identifier>pmid:39340828</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072055</dc:identifier>
</item>
<item>
<title>Plea for an In-Depth Analysis of the RESHAPE-HF2 Results</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39340518/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001082035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 31:S0735-1097(24)08236-6. doi: 10.1016/j.jacc.2024.08.030. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39340518/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001082035&v=2.18.0.post9+e462414">39340518</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.030>10.1016/j.jacc.2024.08.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39340518</guid>
<pubDate>Sat, 28 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jean-François Obadia</dc:creator>
<dc:creator>Xavier Armoiry</dc:creator>
<dc:creator>David Messika-Zeitoun</dc:creator>
<dc:creator>Jean-Noël Trochu</dc:creator>
<dc:creator>Bernard Iung</dc:creator>
<dc:date>2024-09-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Plea for an In-Depth Analysis of the RESHAPE-HF2 Results</dc:title>
<dc:identifier>pmid:39340518</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.030</dc:identifier>
</item>
<item>
<title>CSF proteomics identifies early changes in autosomal dominant Alzheimer's disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39332414/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001082035&amp;v=2.18.0.post9+e462414
      <description>In this high-throughput proteomic study of autosomal dominant Alzheimer's disease (ADAD), we sought to identify early biomarkers in cerebrospinal fluid (CSF) for disease monitoring and treatment strategies. We examined CSF proteins in 286 mutation carriers (MCs) and 177 non-carriers (NCs). The developed multi-layer regression model distinguished proteins with different pseudo-trajectories between these groups. We validated our findings with independent ADAD as well as sporadic AD datasets and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 19:S0092-8674(24)00978-4. doi: 10.1016/j.cell.2024.08.049. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In this high-throughput proteomic study of autosomal dominant Alzheimer's disease (ADAD), we sought to identify early biomarkers in cerebrospinal fluid (CSF) for disease monitoring and treatment strategies. We examined CSF proteins in 286 mutation carriers (MCs) and 177 non-carriers (NCs). The developed multi-layer regression model distinguished proteins with different pseudo-trajectories between these groups. We validated our findings with independent ADAD as well as sporadic AD datasets and employed machine learning to develop and validate predictive models. Our study identified 137 proteins with distinct trajectories between MCs and NCs, including eight that changed before traditional AD biomarkers. These proteins are grouped into three stages: early stage (stress response, glutamate metabolism, neuron mitochondrial damage), middle stage (neuronal death, apoptosis), and late presymptomatic stage (microglial changes, cell communication). The predictive model revealed a six-protein subset that more effectively differentiated MCs from NCs, compared with conventional biomarkers.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39332414/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001082035&v=2.18.0.post9+e462414">39332414</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.049>10.1016/j.cell.2024.08.049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39332414</guid>
<pubDate>Fri, 27 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Yuanyuan Shen</dc:creator>
<dc:creator>Jigyasha Timsina</dc:creator>
<dc:creator>Gyujin Heo</dc:creator>
<dc:creator>Aleksandra Beric</dc:creator>
<dc:creator>Muhammad Ali</dc:creator>
<dc:creator>Ciyang Wang</dc:creator>
<dc:creator>Chengran Yang</dc:creator>
<dc:creator>Yueyao Wang</dc:creator>
<dc:creator>Daniel Western</dc:creator>
<dc:creator>Menghan Liu</dc:creator>
<dc:creator>Priyanka Gorijala</dc:creator>
<dc:creator>John Budde</dc:creator>
<dc:creator>Anh Do</dc:creator>
<dc:creator>Haiyan Liu</dc:creator>
<dc:creator>Brian Gordon</dc:creator>
<dc:creator>Jorge J Llibre-Guerra</dc:creator>
<dc:creator>Nelly Joseph-Mathurin</dc:creator>
<dc:creator>Richard J Perrin</dc:creator>
<dc:creator>Dario Maschi</dc:creator>
<dc:creator>Tony Wyss-Coray</dc:creator>
<dc:creator>Pau Pastor</dc:creator>
<dc:creator>Alan E Renton</dc:creator>
<dc:creator>Ezequiel I Surace</dc:creator>
<dc:creator>Erik C B Johnson</dc:creator>
<dc:creator>Allan I Levey</dc:creator>
<dc:creator>Ignacio Alvarez</dc:creator>
<dc:creator>Johannes Levin</dc:creator>
<dc:creator>John M Ringman</dc:creator>
<dc:creator>Ricardo Francisco Allegri</dc:creator>
<dc:creator>Nicholas Seyfried</dc:creator>
<dc:creator>Gregg S Day</dc:creator>
<dc:creator>Qisi Wu</dc:creator>
<dc:creator>M Victoria Fernández</dc:creator>
<dc:creator>Rawan Tarawneh</dc:creator>
<dc:creator>Eric McDade</dc:creator>
<dc:creator>John C Morris</dc:creator>
<dc:creator>Randall J Bateman</dc:creator>
<dc:creator>Alison Goate</dc:creator>
<dc:creator>Dominantly Inherited Alzheimer Network</dc:creator>
<dc:creator>Laura Ibanez</dc:creator>
<dc:creator>Yun Ju Sung</dc:creator>
<dc:creator>Carlos Cruchaga</dc:creator>
<dc:date>2024-09-27</dc:date>
<dc:source>Cell</dc:source>
<dc:title>CSF proteomics identifies early changes in autosomal dominant Alzheimer's disease</dc:title>
<dc:identifier>pmid:39332414</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.049</dc:identifier>
</item>
<item>
<title>Genomic surveillance as a scalable framework for precision phage therapy against antibiotic-resistant pathogens</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39332413/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001082035&amp;v=2.18.0.post9+e462414
      <description>Phage therapy is gaining increasing interest in the fight against critically antibiotic-resistant nosocomial pathogens. However, the narrow host range of bacteriophages hampers the development of broadly effective phage therapeutics and demands precision approaches. Here, we combine large-scale phylogeographic analysis with high-throughput phage typing to guide the development of precision phage cocktails targeting carbapenem-resistant Acinetobacter baumannii, a top-priority pathogen. Our...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 20:S0092-8674(24)01027-4. doi: 10.1016/j.cell.2024.09.009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Phage therapy is gaining increasing interest in the fight against critically antibiotic-resistant nosocomial pathogens. However, the narrow host range of bacteriophages hampers the development of broadly effective phage therapeutics and demands precision approaches. Here, we combine large-scale phylogeographic analysis with high-throughput phage typing to guide the development of precision phage cocktails targeting carbapenem-resistant Acinetobacter baumannii, a top-priority pathogen. Our analysis reveals that a few strain types dominate infections in each world region, with their geographical distribution remaining stable within 6 years. As we demonstrate in Eastern Europe, this spatiotemporal distribution enables preemptive preparation of region-specific phage collections that target most local infections. Finally, we showcase the efficacy of phage cocktails against prevalent strain types using in vitro and animal infection models. Ultimately, genomic surveillance identifies patients benefiting from the same phages across geographical scales, thus providing a scalable framework for precision phage therapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39332413/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001082035&v=2.18.0.post9+e462414">39332413</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.009>10.1016/j.cell.2024.09.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39332413</guid>
<pubDate>Fri, 27 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Mihály Koncz</dc:creator>
<dc:creator>Tamás Stirling</dc:creator>
<dc:creator>Hiba Hadj Mehdi</dc:creator>
<dc:creator>Orsolya Méhi</dc:creator>
<dc:creator>Bálint Eszenyi</dc:creator>
<dc:creator>András Asbóth</dc:creator>
<dc:creator>Gábor Apjok</dc:creator>
<dc:creator>Ákos Tóth</dc:creator>
<dc:creator>László Orosz</dc:creator>
<dc:creator>Bálint Márk Vásárhelyi</dc:creator>
<dc:creator>Eszter Ari</dc:creator>
<dc:creator>Lejla Daruka</dc:creator>
<dc:creator>Tamás Ferenc Polgár</dc:creator>
<dc:creator>György Schneider</dc:creator>
<dc:creator>Sif Aldin Zalokh</dc:creator>
<dc:creator>Mónika Számel</dc:creator>
<dc:creator>Gergely Fekete</dc:creator>
<dc:creator>Balázs Bohár</dc:creator>
<dc:creator>Karolina Nagy Varga</dc:creator>
<dc:creator>Ádám Visnyovszki</dc:creator>
<dc:creator>Edit Székely</dc:creator>
<dc:creator>Monica-Sorina Licker</dc:creator>
<dc:creator>Oana Izmendi</dc:creator>
<dc:creator>Carmen Costache</dc:creator>
<dc:creator>Ina Gajic</dc:creator>
<dc:creator>Bojana Lukovic</dc:creator>
<dc:creator>Szabolcs Molnár</dc:creator>
<dc:creator>Uzonka Orsolya Szőcs-Gazdi</dc:creator>
<dc:creator>Csilla Bozai</dc:creator>
<dc:creator>Marina Indreas</dc:creator>
<dc:creator>Katalin Kristóf</dc:creator>
<dc:creator>Charles Van der Henst</dc:creator>
<dc:creator>Anke Breine</dc:creator>
<dc:creator>Csaba Pál</dc:creator>
<dc:creator>Balázs Papp</dc:creator>
<dc:creator>Bálint Kintses</dc:creator>
<dc:date>2024-09-27</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Genomic surveillance as a scalable framework for precision phage therapy against antibiotic-resistant pathogens</dc:title>
<dc:identifier>pmid:39332413</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.009</dc:identifier>
</item>
<item>
<title>mTOR activity paces human blastocyst stage developmental progression</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39332412/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001082035&amp;v=2.18.0.post9+e462414
      <description>Many mammals can temporally uncouple conception from parturition by pacing down their development around the blastocyst stage. In mice, this dormant state is achieved by decreasing the activity of the growth-regulating mTOR signaling pathway. It is unknown whether this ability is conserved in mammals in general and in humans in particular. Here, we show that decreasing the activity of the mTOR signaling pathway induces human pluripotent stem cells (hPSCs) and blastoids to enter a dormant state...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 18:S0092-8674(24)00977-2. doi: 10.1016/j.cell.2024.08.048. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Many mammals can temporally uncouple conception from parturition by pacing down their development around the blastocyst stage. In mice, this dormant state is achieved by decreasing the activity of the growth-regulating mTOR signaling pathway. It is unknown whether this ability is conserved in mammals in general and in humans in particular. Here, we show that decreasing the activity of the mTOR signaling pathway induces human pluripotent stem cells (hPSCs) and blastoids to enter a dormant state with limited proliferation, developmental progression, and capacity to attach to endometrial cells. These in vitro assays show that, similar to other species, the ability to enter dormancy is active in human cells around the blastocyst stage and is reversible at both functional and molecular levels. The pacing of human blastocyst development has potential implications for reproductive therapies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39332412/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001082035&v=2.18.0.post9+e462414">39332412</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.048>10.1016/j.cell.2024.08.048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39332412</guid>
<pubDate>Fri, 27 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Dhanur P Iyer</dc:creator>
<dc:creator>Heidar Heidari Khoei</dc:creator>
<dc:creator>Vera A van der Weijden</dc:creator>
<dc:creator>Harunobu Kagawa</dc:creator>
<dc:creator>Saurabh J Pradhan</dc:creator>
<dc:creator>Maria Novatchkova</dc:creator>
<dc:creator>Afshan McCarthy</dc:creator>
<dc:creator>Teresa Rayon</dc:creator>
<dc:creator>Claire S Simon</dc:creator>
<dc:creator>Ilona Dunkel</dc:creator>
<dc:creator>Sissy E Wamaitha</dc:creator>
<dc:creator>Kay Elder</dc:creator>
<dc:creator>Phil Snell</dc:creator>
<dc:creator>Leila Christie</dc:creator>
<dc:creator>Edda G Schulz</dc:creator>
<dc:creator>Kathy K Niakan</dc:creator>
<dc:creator>Nicolas Rivron</dc:creator>
<dc:creator>Aydan Bulut-Karslioğlu</dc:creator>
<dc:date>2024-09-27</dc:date>
<dc:source>Cell</dc:source>
<dc:title>mTOR activity paces human blastocyst stage developmental progression</dc:title>
<dc:identifier>pmid:39332412</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.048</dc:identifier>
</item>
<item>
<title>Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39332395/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001082035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this prespecified secondary analysis of the FINEARTS-HF randomized clinical trial, long-term treatment with finerenone was estimated to extend event-free survival by up to 3 years among people with HF with mildly reduced or preserved ejection fraction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 27. doi: 10.1001/jamacardio.2024.3782. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: People living with heart failure (HF) with mildly reduced or preserved ejection fraction have substantially curtailed life expectancy free from clinical events compared with their peers of comparable age. The nonsteroidal mineralocorticoid receptor antagonist, finerenone, was recently shown to reduce risks of cardiovascular events in this population over a median follow-up of 2.6 years; as patients with HF typically continue treatment beyond this time frame, estimating the potential long-term benefits of finerenone could inform shared clinical decision-making.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To estimate the projected long-term treatment effects of finerenone in patients with HF with mildly reduced or preserved ejection fraction if treated over a patient's lifetime.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Prespecified analyses were conducted of the FINEARTS-HF trial, a phase 3 randomized clinical trial conducted across 653 sites in 37 countries. Adults 40 years and older with symptomatic HF and left ventricular ejection fraction of 40% or greater were randomized from September 2020 to January 2023. Median (IQR) follow-up was 2.6 (1.9-3.0) years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Finerenone (titrated to either 20 mg or 40 mg) or placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary composite outcome was time to cardiovascular death or worsening HF event. The long-term gains in survival free from a primary end point with finerenone were iteratively estimated with age-based Kaplan-Meier curves using age at randomization rather than time from randomization. Differences in areas under the survival curves between the finerenone and placebo arms represented event-free survival gains.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 6001 participants (median [IQR] age, 73 [66-79] years; 3269 male [54.5%]), mean survival free from the primary end point for a 55-year-old participant was 13.6 years (95% CI, 11.9-15.2 years) with finerenone and 10.5 years (95% CI, 6.8-11.3 years) with placebo, representing a gain in event-free survival of 3.1 years (95% CI, 0.8-5.4 years; P = .007). Mean event-free survival for a 65-year-old participant was 11.0 years (95% CI, 10.1-11.9 years) with finerenone and 8.9 years (95% CI, 8.1-9.8 years) with placebo, representing a gain of 2.0 years (95% CI, 0.8-3.3 years; P = .001). Projected mean event-free survival was numerically greater with finerenone than with placebo for every starting age between 50 to 80 years. Lifetime gains in event-free survival were observed even among individuals already treated with a sodium-glucose cotransporter 2 inhibitor (65-year-old participant: 3.1 years; 95% CI, 0.1-6.0 years; P = .04).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this prespecified secondary analysis of the FINEARTS-HF randomized clinical trial, long-term treatment with finerenone was estimated to extend event-free survival by up to 3 years among people with HF with mildly reduced or preserved ejection fraction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39332395/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001082035&v=2.18.0.post9+e462414">39332395</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3782>10.1001/jamacardio.2024.3782</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39332395</guid>
<pubDate>Fri, 27 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Maria Borentian</dc:creator>
<dc:creator>James Lay-Flurrie</dc:creator>
<dc:creator>Prabhakar Viswanathan</dc:creator>
<dc:creator>Friederike U Behmenburg</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-09-27</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39332395</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3782</dc:identifier>
</item>





























</channel>
</rss>